260 related articles for article (PubMed ID: 3158265)
1. Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
McRoyan DK; McRoyan CJ; Sauter KL; Liu PI; Daniel SJ
Ann Clin Lab Sci; 1985; 15(2):165-70. PubMed ID: 3158265
[TBL] [Abstract][Full Text] [Related]
2. Changes in the coagulation and fibrinolytic systems during and after cardiopulmonary bypass surgery.
Kongsgaard UE; Smith-Erichsen N; Geiran O; Bjørnskau L
Thorac Cardiovasc Surg; 1989 Jun; 37(3):158-62. PubMed ID: 2527423
[TBL] [Abstract][Full Text] [Related]
3. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
4. [Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome].
Kobayashi M; Katayama T; Ochiai S; Yoshida M; Kaito K; Masuoka H; Shimada T; Nishiwaki K; Sakai O
Nihon Jinzo Gakkai Shi; 1991 Jul; 33(7):653-8. PubMed ID: 1836241
[TBL] [Abstract][Full Text] [Related]
5. The immunochemical determination of thrombin-antithrombin III and plasmin-antiplasmin complexes in human plasma.
Collen D
Verh K Acad Geneeskd Belg; 1979; 41(2):81-166. PubMed ID: 160714
[No Abstract] [Full Text] [Related]
6. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
Holvoet P; de Boer A; Verstreken M; Collen D
Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
[TBL] [Abstract][Full Text] [Related]
7. Homozygous type I plasminogen deficiency.
Mingers AM; Heimburger N; Zeitler P; Kreth HW; Schuster V
Semin Thromb Hemost; 1997; 23(3):259-69. PubMed ID: 9255907
[TBL] [Abstract][Full Text] [Related]
8. Effects of exploratory laparotomy on plasma and peritoneal coagulation/fibrinolysis in horses.
Baxter GM; Parks AH; Prasse KW
Am J Vet Res; 1991 Jul; 52(7):1121-7. PubMed ID: 1892267
[TBL] [Abstract][Full Text] [Related]
9. [Antithrombin III and alpha 2-plasmin inhibitor in DIC--the significance of their levels and existence of complexes as diagnostic indicators].
Tsuda T; Hayashi H; Tsurumi N; Kuroda M; Takai Y; Kimura I
Rinsho Ketsueki; 1985 Mar; 26(3):332-40. PubMed ID: 3162051
[No Abstract] [Full Text] [Related]
10. Serum antithrombin III and alpha-2-antiplasmin concentration in patients with lung carcinoma.
Dabrowska M; Prokopowicz J; Kemona H; Kretowska J; Kulik S; Głuszczak M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):641-6. PubMed ID: 2465244
[TBL] [Abstract][Full Text] [Related]
11. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy.
Nowak-Göttl U; Rath B; Binder M; Hassel JU; Wolff J; Husemann S; Ritter J
Haematologica; 1995; 80(5):451-3. PubMed ID: 8566890
[TBL] [Abstract][Full Text] [Related]
12. The influence of age on in vitro plasmin generation in the presence of fibrin monomer.
Parmar N; Mitchell LG; Berry LR; Andrew M; Chan AK
Acta Haematol; 2006; 115(3-4):141-51. PubMed ID: 16549888
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of antithrombin III, plasminogen and alpha 2-plasmin inhibitor in perinatal period.
Fuse Y; Fuse K
Asia Oceania J Obstet Gynaecol; 1985 Mar; 11(1):121-5. PubMed ID: 3160323
[No Abstract] [Full Text] [Related]
14. [Recent progress on analysis of blood coagulation factors and fibrinolytic agents; new synthetic chromogenic substrate assays for hemostatic parameters].
Hiura H; Nishiyama T; Kimura M; Matoba K; Hayashi O; Sasaki M; Ishijima C; Irie Y; Yasuda N
Rinsho Byori; 1989 Apr; Spec No 81():214-9. PubMed ID: 2754808
[No Abstract] [Full Text] [Related]
15. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
[TBL] [Abstract][Full Text] [Related]
16. [Recent progress on analysis of blood coagulation factors and fibrinolytic agents; measurement with new synthetic substrate method].
Ujiie M; Kuroiwa K; Nagasawa T; Sato Y; Kitahara N
Rinsho Byori; 1989 Apr; Spec No 81():208-13. PubMed ID: 2754807
[No Abstract] [Full Text] [Related]
17. [Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation].
Fukuda C; Iijima K; Nakamura K
Rinsho Byori; 1996 Aug; 44(8):750-6. PubMed ID: 8816061
[TBL] [Abstract][Full Text] [Related]
18. [Hemostasis in burn patients and treatment with heparin. Relation to prognosis and infection. Pattern of blood levels of prekallikrein, alpha-2-macroglobulin, antithrombin III, plasminogen and alpha-2-antiplasmin].
Hainaut J; Dhennin C; Guilbaud J
Nouv Rev Fr Hematol (1978); 1982; 24(6):375-81. PubMed ID: 6188103
[TBL] [Abstract][Full Text] [Related]
19. Synthetic peptide substrates in hemostatic testing.
Fareed J; Messmore HL; Walenga JM; Bermes EW
Crit Rev Clin Lab Sci; 1983; 19(2):71-134. PubMed ID: 6373139
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin and other DIC-related variables in patients with moderately severe infections receiving cryoprecipitate.
Brodin B; Hesselvik F; Blombäck M; Cedergren B; Lieden G; Maller R; Strindberg J
Scand J Clin Lab Invest Suppl; 1985; 178():57-65. PubMed ID: 3937219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
